directly genotyped SNP from case-control analyses (rs10764338) was again significantly associated with an increased risk for hyperdiploid B-ALL (OR, 2.47; 95% CI, 1.42-4.29; $P = 9.8 \times 10^{-4}$).

Although risk loci in *ARID5B* have been shown to confer a greater risk for hyperdiploid B-ALL vs other subtypes,^{2,4} the risk loci in *BMI1-PIP4K2A* reported here are the first to be exclusively associated with this ALL subtype. Our results confirm that variation at chr10p12.31-12.2 confers a risk for childhood ALL and further indicates that these variants distinguish hyperdiploid B-ALL from other subtypes. Finemapping via SNP imputation refined the association peak to a ~35kb region in *PIP4K2A*, which includes a rare variant (rs142846483; minor allele frequency in controls = 0.011) conferring an exceptionally high risk for hyperdiploid B-ALL among Hispanic children (OR, 15.15; 95% CI, 4.57-50.21 $P = 8.8 \times 10^{-6}$).

The risk variants identified by Xu et al do not affect protein coding, although they found that the rs7088318 risk allele was associated with increased *PIP4K2A* messenger RNA expression.¹ Our most strongly associated SNPs were also intronic, suggesting that variants in *PIP4K2A* that confer risk for hyperdiploid B-ALL may be regulatory in nature, as has been observed in fine-mapping studies of other neoplastic diseases.^{6,7}

Kyle M. Walsh

Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center and Division of Neuroepidemiology, Department of Neurological Surgery, University of California, San Francisco San Francisco, CA

Adam J. de Smith

Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA

Anand P. Chokkalingam

School of Public Health, University of California Berkeley, Berkeley, CA

Catherine Metayer

School of Public Health, University of California Berkeley, Berkeley, CA

Gary V. Dahl

Division of Pediatric Hematology/Oncology, Department of Pediatrics, Stanford School of Medicine, Stanford, CA

Ling-i Hsu

School of Public Health, University of California Berkeley, Berkeley, CA

Lisa F. Barcellos

School of Public Health, University of California Berkeley, Berkeley, CA Joseph L. Wiemels

Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA

Patricia A. Buffler

School of Public Health, University of California Berkeley, Berkeley, CA

K.M.W. and A.J.d.S. contributed equally to this work.

Acknowledgments: The authors gratefully acknowledge the clinical investigators at the following collaborating hospitals for help in recruiting patients: University of California Davis Medical Center (Dr Jonathan Ducore), University of California San Francisco (Drs Mignon Loh and Katherine Matthay), Children's Hospital of Central California (Dr Vonda Crouse), Lucile Packard Children's Hospital (Dr Gary Dahl), Children's Hospital Oakland (Dr James Feusner), Kaiser Permanente Roseville (formerly Sacramento) (Drs Kent Jolly and Vincent Kiley), Kaiser Permanente Santa Clara (Drs Carolyn Russo, Alan Wong, and Denah Taggar), Kaiser Permanente San Francisco (Dr Kenneth Leung), and Kaiser Permanente Oakland (Drs Daniel Kronish and Stacy Month).

Contribution: K.M.W., A.J.d.S., and J.L.W. conceived and designed the study; L.F.B., P.A.B., A.P.C., G.V.D., L.H., C.M., K.M.W., and J.L.W. assisted in assembling the data; K.M.W. analyzed and interpreted the data; A.J.d.S. and K.M.W. wrote the manuscript; and all authors critically reviewed and edited the manuscript for intellectual content and gave final approval of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Kyle M. Walsh, University of California, San Francisco Helen Diller Family Cancer Center, Box 0520, 1450 3rd St HD276, San Francisco, CA; e-mail: kyle.walsh@ucsf.edu.

References

- Xu H, Yang W, Perez-Andreu V, et al. Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst. 2013; Mar 19. [Epub ahead of print].
- Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. *Nat Genet*. 2009;41(9):1006-1010.
- Sherborne AL, Hosking FJ, Prasad RB, et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. *Nat Genet.* 2010;42(6): 492-494.
- Treviño LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. *Nat Genet*. 2009;41(9):1001-1005.
- Bartley K, Metayer C, Selvin S, Ducore J, Buffler P. Diagnostic X-rays and risk of childhood leukaemia. Int J Epidemiol. 2010;39(6):1628-1637.
- Jenkins RB, Xiao Y, Sicotte H, et al. A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. *Nat Genet.* 2012;44(10):1122-1125.
- Spain SL, Carvajal-Carmona LG, Howarth KM, et al. Refinement of the associations between risk of colorectal cancer and polymorphisms on chromosomes 1q41 and 12q13.13. *Hum Mol Genet.* 2012;21(4):934-946.

To the editor:

Gender influences the birth order effect in HLA-identical stem cell transplantation

An earlier report by Bucher et al¹ indicated a better stem cell transplant (SCT) outcome with younger sibling donors (YSD). Transmaternal cell flow during pregnancy² might explain this observation. Notably, cord blood comprises minor H antigen experienced T cells that are not only directed against maternal foreign minor H antigens.^{3,4} This observation prompted us to investigate the role of minor H antigens in the birth order effect in HLA identical SCT.

Hereto, we made use of a large database of 10/10 HLA allelematched and minor H antigen-typed SCT donor/recipient pairs (Spierings et al, submitted), collected under the auspices of the International Histocompatibility and Immunogenetics Workshop and Conference. Additional relevant family information was included for 311 10/10 HLA allele-matched sibling donor/ recipient pairs.



Figure 1. Influence of birth order on overall survival and GVHD incidence. (A) Overall survival and GVHD incidence in recipients with a YSD (n = 168) compared with recipients with an OSD (n = 143) are not statistically significantly different. (B) Female donors with female recipients have a higher non-GVHD death incidence (ie, relapse) in YSD compared with OSD (hazard ratio = 3.76, P = .094). (C) Adult YSD are subdivided by gender. Female donors in female recipients have a significantly (P = .008) reduced GVHD incidence compared with M \rightarrow M.

In the whole cohort of 311 pairs, overall survival, graft versus host disease (GVHD) incidence, GVHD-related mortality, and GVHD-free survival were not statistically significantly different in SCT with older sibling donors (OSD, n = 143) compared with SCT with YSD (n = 168; Figure 1A).

The sample size of 311 appeared too small to analyze the effect of either single or multiple autosomally or of single Y chromosome– encoded minor H antigen(s). However, the effect of gender mismatch⁵ on the birth order effect appeared feasible to investigate. Interaction analyses of birth order and gender mismatch showed a statistically significant interaction for non-GVHD, which is merely relapse-related, death (P < .05; data not shown). Subsequent analysis in female recipients of female donors ($F \rightarrow F$; Figure 1B) showed lower, nonsignificant non–GVHD-related death in the YSD group (hazard ratio = 3.76, P = .094).

The study cohort comprised pediatric and adult SCT pairs. The number of pediatric pairs (n = 40) was too small to analyze separately. Analysis of the adult SCT pairs revealed a significant reduced GVHD incidence in the YSD group as opposed to the OSD group by comparing F \rightarrow F transplantation with male donors to male recipients (M \rightarrow M) transplantation (hazard ratio = 0.337, P = .008; Figure 1C). Furthermore, GVHD-free survival

Brigitte Kircher

Immunobiology and Stem Cell Laboratory, Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria

David Laurin

Establissement Francais du Sang Rhône-Alpes, TheREx, Centre National de la Recherche Scientifique, Université Joseph Fourier, Unité Mixte de Recherche 5525, Grenoble, France

Pascale Loiseau

Laboratoire d'Immunologie, Hopital Saint-Louis, Paris, France

Ruhena Sergeant

Clinical Immunology Laboratory, Hammersmith Hospital, London, United Kingdom

Els Goulmy

Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands

Contribution: M.D., E.S., and E.G. designed the research and drafted the manuscript; A.C., H.D., J.-F.E., J.E., T.G., B.K., D.L., P.L., and R.S. provided data; M.D., E.S., and M.H. collected data; and M.D., E.S., R.B., and E.G. analyzed results and prepared figures.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Eric Spierings, Laboratory for Translational Immunology, University Medical Center Utrecht, F03.821, Postbox 85500, 3508 GA, Utrecht, Netherlands; e-mail: e.spierings@umcutrecht.nl.

References

- Bucher C, Stern M, Buser A, et al. Role of primacy of birth in HLA-identical sibling transplantation. *Blood.* 2007;110(1):468-469.
- Gammill HS, Guthrie KA, Aydelotte TM, Adams Waldorf KM, Nelson JL. Effect of parity on fetal and maternal microchimerism: interaction of grafts within a host? *Blood.* 2010;116(15):2706-2712.
- Mommaas B, Stegehuis-Kamp JA, van Halteren AG, et al. Cord blood comprises antigen-experienced T cells specific for maternal minor histocompatibility antigen HA-1. *Blood.* 2005;105(4):1823-1827.
- Dierselhuis MP, Blokland EC, Pool J, Schrama E, Scherjon SA, Goulmy E. Transmaternal cell flow leads to antigen-experienced cord blood. *Blood*. 2012; 120(3):505-510.
- Loren AW, Bunin GR, Boudreau C, et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2006;12(7):758-769.
- Dobbelstein C, Ahn KW, Haagenson M, et al. Birth order and transplant outcome in HLA-identical sibling stem cell transplantation: an analysis on behalf of the Center for International Blood and Marrow Transplantation (CIBMTR). *Biol Blood Marrow Transplant*. 2013;19(5):741-745.
- van Halteren AGS, Jankowska-Gan E, Joosten A, et al. Naturally acquired tolerance and sensitization to minor histocompatibility antigens in healthy family members. *Blood.* 2009;114(11):2263-2272.

was significantly better in $F \rightarrow F$ compared with $M \rightarrow M$ SCT (hazard ratio = 0.547, P = .043; data not shown).

In summary, we support the existence of a birth order effect as reported before.^{1,6} Additionally, we show that gender might be one of the causal factors. Interestingly, the birth order effect was significant in the adult female donor/female recipient SCT pairs. Our current plausible explanation is the intrauterine exposure to sibling antigens occurring during pregnancy, leading to minor H antigen experienced T-cell responses in women.⁴ These responses might lead to immune regulation.⁷ Subsequent (re-)exposure to fetal antigens during pregnancy of the donor herself explains the favorable younger female SCT donor in combination with the female recipient.

To get a clearer picture of the influence of minor H antigens on the birth order effect, we suggest a much larger cohort of HLA-identical sibling SCT with detailed information regarding family and obstetric history of both patient and donor.

Miranda P. Dierselhuis

Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands

Eric Spierings

Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands

Ronald Brand

Department of Medical Statistics and Biostatistics, Leiden University Medical Center, Leiden, The Netherlands

Matthijs Hendriks

Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands

Angelica Canossi

Istituto CNR Trapianti D'Organo e l'Immunocitologia, L'Aquila, Italy

Harry Dolstra

Central Hematology Laboratory, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Jean-François Eliaou

Centre Hospitalier Universitaire, Montpellier Unité d'Immunogénétique, Laboratoire d'Immunologie, Hopital Saint-Eloi, Montpellier, France

Jürgen Enczmann

Institute for Transplantation Immunology, University Hospital, Düsseldorf, Germany

Thibaut Gervais

Immunohaematology, Cliniques St Luc, Université Catholique de Louvain, Brussels, Belgium